Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure

Back

HFA Premium Access

Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure

Session: Advances in GLP1-RAs, SGLT2 inhibitors and more

Topic: Pharmacotherapy

Speaker: Ms S. Ugovsek (Ljubljana, SI)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Ms Sabina Ugovsek

University Medical Centre Ljubljana, Ljubljana (Slovenia)

0 follower

4 more presentations in this session

Impact of individual components of quadruple therapy in octagenerian heart failure patients: results from a real life data

Speaker: Associate Professor I. Colluoglu (Karabuk, TR)

Dapagliflozin for heart failure with reduced ejection fraction: early experience of treatment adherence and impact on patient-reported outcomes in EVOLUTION HF, a multinational, observational study

Speaker: Professor J. Cardoso (Porto, PT)

Titration of sacubitril/valsartan in acute heart failure

Speaker: Doctor S. Doi (Kawasaki, JP)

The effect of glucagon-like peptide-1 receptor agonists on patients with heart failure with reduced ejection fraction

Speaker: Doctor Z. Iakobishvili (Tel Aviv, IL)

Access the full session

Advances in GLP1-RAs, SGLT2 inhibitors and more

Speakers: Ms S. Ugovsek, Associate Professor I. Colluoglu, Professor J. Cardoso, Doctor S. Doi, Doctor Z. Iakobishvili

Access

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources